Shelved forty years, an old Alzheimer's theory finds vindication in imaging
A young scientist uses imaging data to show that degradation of deep-brain cholinergic neurons precedes, rather than follows, cortical amyloid deposition—reviving an old theory sidelined by the amyloid hypothesis.
The video won't play here. Listen to the audio instead:
The argument · tap a timestamp to hear it
Drug-induced amnesia led researchers to the cholinergic hypothesis
Researchers discovered that drugs blocking acetylcholine signaling induced a memory deficit resembling that seen in aging and early Alzheimer's. Subsequent autopsy studies found that the nucleus basalis of Meynert—a deep-brain hub where cholinergic neurons project to cortical memory and attention areas—was severely damaged late in disease. This led pathologists to suspect it was among the earliest damaged structures. By the early 1980s these findings coalesced into the cholinergic hypothesis: Alzheimer's memory loss and age-related memory loss might be the same process, differing only in degree.
— Jenny SmithThe amyloid hypothesis displaced both the old theory and old drugs
When the amyloid hypothesis was formally proposed in the early 1990s, a cohort of cholinergic molecules already showing promise—including drugs targeting cognitive receptors with fewer side effects—was shelved outright. The entire field pivoted to focus on the protein deemed the culprit. Mutations in familial Alzheimer's patients all pointed to amyloid generation pathways; the evidence seemed "locked in," and cholinergic research was crowded out of mainstream view.
— Jenny SmithAmyloid drugs clear plaques beautifully but barely improve cognition
Anti-amyloid antibodies do cleanly remove plaques and their precursor forms, but the cognitive benefit is only "30% slowing" of decline—not improvement—and temporary and limited. This gap has led researchers to revive shelved cholinergic drugs. Xanomeline, originally developed for schizophrenia (now marketed as Cobenfy), showed in early trials on Alzheimer's patients that it could improve cognition; it's being retested now.
— Jenny SmithImaging data challenges where Alzheimer's begins
A recently graduated young scientist used MRI and PET data to challenge the conventional wisdom: does Alzheimer's really start in the entorhinal cortex? His research showed instead that nucleus basalis of Meynert (the cholinergic hub) degeneration predicts subsequent entorhinal changes, not the reverse. New tools like optogenetics let researchers for the first time observe these neurons in detail, refocusing the field on the overlooked deep-brain structures.
— Jenny SmithAmerica's power grid bottleneck is policy, not engineering
Despite heavy investment, America has built high-voltage transmission lines and capacity very slowly over recent decades. Near-term consequences: surging data-center demand pushes up electricity prices. Long-term: harder transition to renewables and less resilience against extreme weather outages lasting days. Technology is not the bottleneck; incentives and policy design are.
— Madeline YazwickTerritorial monopolies lock in rules from the 1930s
In the 1920s–30s, multiple utilities duplicated lines in the same regions, inefficiently, while large areas had no power at all. States granted single companies exclusive supply rights for specific territories in exchange for giving up pricing power; the state approved cost recovery. This "territorial" governance model persists, but problems now exceed single-company jurisdictions. Utah solar reaching Las Vegas requires cross-state coordination no one company can deliver.
— Madeline YazwickDirect current lets power lines hide underground
U.S. transmission relies on AC; long-distance DC was historically too expensive. Voltage source converter (VSC-HVDC) technology now makes DC economic in some cases. The advantage: cables bury underground along existing roads and rail corridors—the Champlain-Hudson line in New York runs directly under the Hudson River. This avoids seizing private land and sidesteps opposition to high-voltage towers, potentially speeding project completion.
— Madeline YazwickEvery patient carries a drug-response genetic variant
Among ~100,000 All of Us participants with whole-genome data, researchers tested 16 common drug-response genes; every patient carried at least one variant. Critically, roughly one-quarter were already taking drugs affected by their variants—not a rare edge case but a routine clinical issue. The study also uncovered 17,000 previously unreported variants in these genes, providing frequency data needed to decide which populations should be tested and when.
— Philip EmpeyIn their own words · checked verbatim
giving people drugs that were known to interrupt acetylcholine signaling could induce a type of memory deficit that was very reminiscent of the sort of selective memory deficit seen among people as they age
Jenny Smith2:04
These drugs that were developed in the 1990s were just kind of shelved in the whole entire field, sort of began to focus on what it considered the biological basis for Alzheimer's disease.
Jenny Smith8:14
it's actually kind of on par, like a 30% slowing of decline, not an improvement, but a slowing of decline. So you're really looking at a temporary and modest benefit.
Jenny Smith9:20
he actually showed that degradation in that hub predicted what would happen in the entorhinal cortex and not the other way around.
Jenny Smith12:25
One scientist described them to me as fragile little noodles, little fragile glass noodles.
Jenny Smith16:35
You know, no one likes losing their power for eight hours, 12 hours, multiple days a week.
Madeline Yazwick23:51
The advantage of doing that, the advantage of DC is that you can actually bury the transmission line. So it doesn't need to be above ground.
Madeline Yazwick34:06
Figures
| Cognitive benefit of anti-amyloid drugs | 30% slowing of decline | 9:20 |
| Common drug-response genes tested | 16 | 43:22 |
| Patients already taking affected drugs | About one-quarter | 43:22 |
| Previously unreported genetic variants discovered | 17,000 | 47:27 |
Glossary
- cholinergic hypothesis
- Theory that Alzheimer's originates in damage to the brain's acetylcholine system.
- nucleus basalis of Meynert
- Deep-brain hub where cholinergic neurons project to memory and attention regions of the cortex.
- HVDC
- High-voltage direct current transmission technology that enables long-distance power lines with cables that can bury underground.
- All of Us
- The NIH research program collecting genome and health data from large U.S. participant cohorts.
- pharmacogenomics
- The study of how genetic variations affect individual drug response and metabolism.
How to listen
Investors tracking neurodegenerative disease research, entrepreneurs studying power-grid policy, and healthcare practitioners interested in precision medicine implementation.
Skip the opening and closing AAAS membership promotion bumpers; all three interview segments are worth hearing.